trending Market Intelligence /marketintelligence/en/news-insights/trending/fkdfcsehcv7jgxiibjkbdg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

MediciNova's ALS treatment orphan-drug designated in Europe

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


MediciNova's ALS treatment orphan-drug designated in Europe

The European Commission designated as an orphan drug MediciNova Inc.'s MN-166 treatment for amyotrophic lateral sclerosis, or ALS.

The development offers potential benefits including protocol assistance, fee reductions and a 10-year market exclusivity once the medicine is introduced in the European market.

The drug is also designated as an orphan drug for ALS in the U.S. and is marketed in Japan and Korea to treat post-stroke complications and bronchial asthma.